Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials

July 7, 2026 11:25 AM EDTUpdated 12:19 PM R&DChina Hen­grui, Kail­er­a's GLP-1 pill posts en­cour­ag­ing ef­fi­ca­cy but high side ef­fect rates in late-stage Chi­na tri­als Elizabeth Cairns Senior biopharma journalist The GLP-1 pill be­ing de­vel­oped by Hen­grui Phar­ma and Kail­era Ther­a­peu­tics post­ed de­cent re­sults in two late-stage Chi­na-based tri­als — one in obe­si­ty and the oth­er … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER